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Clinically early-stage CSPα mutation carrier
exhibits remarkable terminal stage
neuronal pathology with minimal evidence
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Abstract
Autosomal dominant adult-onset neuronal ceroid lipofuscinosis (AD-ANCL) is a multisystem disease caused by
mutations in the DNAJC5 gene. DNAJC5 encodes Cysteine String Protein-alpha (CSPα), a putative synaptic protein.
AD-ANCL has been traditionally considered a lysosomal storage disease based on the intracellular accumulation of
ceroid material. Here, we report for the first time the pathological findings of a patient in a clinically early stage of
disease, which exhibits the typical neuronal intracellular ceroid accumulation and incipient neuroinflammation but
no signs of brain atrophy, neurodegeneration or massive synaptic loss. Interestingly, we found minimal or no
apparent reductions in CSPα or synaptophysin in the neuropil. In contrast, brain homogenates from terminal
AD-ANCL patients exhibit significant reductions in SNARE-complex forming presynaptic protein levels, including a
significant reduction in CSPα and SNAP-25. Frozen samples for the biochemical analyses of synaptic proteins were
not available for the early stage AD-ANLC patient. These results suggest that the degeneration seen in the patients
with AD-ANCL reported here might be a consequence of both the early effects of CSPα mutations at the cellular
soma, most likely lysosome function, and subsequent neuronal loss and synaptic dysfunction.
Keywords: Neuronal ceroid lipofuscinosis, Cysteine string protein alpha, Synaptic loss, Neurodegenerative disease,
Lysosome DNAJC5
Background
The neuronal ceroid lipofuscinoses (NCLs) are the most
common group of inherited neurodegenerative diseases
in children [1]. NCLs are a genetically, clinically and
pathologically heterogeneous group of disorders, unified
by the presence of intracellular accumulation of auto-
fluorescent ceroid-lipofuscin aggregates (a complex mix-
ture of proteins, lipids and metals) [1, 2]. The age at
onset of clinical symptoms and differences in ultrastruc-
tural features of the storage material underlie the noso-
logical spectrum of NCLs [1, 2]. NCLs are traditionally
considered lysosomal storage diseases (LSD), even
though several of the mutant proteins are not primary
lysosomal proteins. The function of some of these pro-
teins is largely unknown and their relationship to lyso-
some function is unclear [3].
Adult-onset NCLs (ANCL) represent up to 10 % of
NCL cases [4]. ANCL patients exhibit the typical auto-
fluorescent granular osmiophilic deposits (GROD) in
neurons and skin cells [4, 5]. In recent years, the pro-
gress in sequencing technology has supported the identi-
fication of a plethora of novel disease-causing genes in
multiple families with ANCL-like clinical features and
GROD-type storage material. This indicates that the
genetic architecture of ANCL is more varied and com-
plex than previously thought [3].
Most NCLs have a recessive pattern of inheritance; one
exception is the autosomal dominant, adult onset neur-
onal ceroid lipofuscinosis (AD-ANCL) (MIM #162350).
AD-ANCL patients are asymptomatic until around the
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third decade [5]. The first symptom is usually new-onset
seizures (tonic-clonic type) followed by rapid cognitive
decline, motor impairment and finally, death in the ab-
sence of visual impairments [5]. The primary clinical and
pathological features of AD-ANCL include progressive
and widespread neurodegenerative processes resulting in
remarkable cortical and cerebellar atrophy [5]. Nearly all
of our current understanding of AD-ANCL is based on
analysis of postmortem tissue from terminal cases. To our
knowledge, there is no report characterizing both early
and late pathology events of AD-ANCL cases.
AD-ANCL is caused by a heterozygous point mutation
(p.L115R) and an in-frame codon deletion (p.L116Δ) in
the DnaJ (Hsp40) homolog, subfamily C, member 5
(DNAJC5) gene [6–8]. The DNAJC5 gene encodes CSPα.
CSPα is a cytosolic and membrane-bound co-chaperone
with a putative neuroprotective function [9]. The func-
tion of CSPα in the central nervous system is primarily
deduced from data collected from CSPα-deficient mice
and flies, which exhibit massive age-dependent neurode-
generation affecting mainly active neurons and photore-
ceptors [9, 10]. CSPα is widely considered a member of
the presynaptic machinery responsible for proteostasis
and synapse maintenance [11–13]. Defective synaptic
soluble NSF attachment protein receptor (SNARE)-
complex assembly, due mostly but not exclusively to the
reduction in soluble NSF attachment protein-25 (SNAP-
25) levels, appears to be responsible for the neurodegen-
eration seen in CSPα-deficient mice [10, 11, 14, 15].
There are approximately 20 additional proteins that
demonstrate altered expression patterns in the absence
of CSPα in mice [13] that can also be part of its patho-
genic cascade.
The histological hallmark of AD-ANCL is the intra-
cellular accumulation of autofluorescent storage ma-
terial (AFSM) [4, 5]. Although there are similarities in
the neurodegenerative process between AD-ANCL
patients and CSPα-deficient mice, no ceroid accumu-
lation has been reported in CSPα-deficient mice or
flies [12, 16]. Currently, it is unknown how mutations
in DNAJC5/CSPα result in the formation of AFSM. A
dominant negative effect was initially proposed as the
pathogenic mechanism for AD-ANCL-causing muta-
tions in CSPα based on both its inheritance pattern
and a reduction in neuropil CSPα staining in terminal
AD-ANCL cases [7, 12, 17].
In this report, we describe the clinical and patho-
logical features of a patient in a clinically early stage of
the disease with all the pathological cellular changes
found in terminal AD-ANCL cases but with no apparent
reduction in CSPα or synaptophysin in the neuropil. In
contrast, terminal AD-ANCL patients exhibit significant
reductions of presynaptic protein levels, including a




Reverse, 5'-cggcacagtgtcagtgccctcc-3') was amplified on
Applied Biosystems (Applied Biosystems, Carlsbad,
California, USA) 96-Well GeneAmp® PCR System
9700 Thermal Cyclers using a touchdown protocol.
PCR products were amplified under the same conditions
(25-μl volume containing 10× PfuUltra™ HF reaction
buffer (Stratagene, La Jolla, California, USA), 5× Betaine
(Sigma-aldrich, St Louis, USA), 100 μM each dNTP,
200 nM each primer, 0.4 PfuUltra™ High-Fidelity DNA
Polymerase (Promega); PCR profile: 94 °C followed by
34 cycles of 45 s at 94 °C, 45 s at 62°, and 1 min at 72 °C).
PCR product purification was completed with Exosap-IT
(USB Corporation). Sequencing was performed both in
forward and reverse direction using BigDye® Terminator
v3.1 Cycle Sequencing Kit (ABI) on an ABI 3130 sequen-
cer. Sequence traces were analyzed using Sequencher
(v4.7, Gene Codes Corp, Ann Arbor, Michigan, USA).
Neuropathological Methods
After death, the consent for brain removal was obtained
from next-of-kin. Briefly, the left hemibrain was pre-
served in 10 % phosphate-buffered formalin for neuro-
pathologic assessment; the right hemibrain was snap
frozen and stored at −80 °C for biochemical studies [18].
Unfortunately, no flash frozen tissue was obtained from
the early stage AD-ANCL patient. Tissue blocks were
taken from the frontal, temporal, parietal, and occipital
lobes, amygdala, hippocampus, basal ganglia, thalamus,
brainstem, cerebellum, and spinal cord when available.
Following formic acid (95 %) pretreatment for 5 min,
histology was undertaken and included hematoxylin and
eosin and a modified Bielschowsky silver impregnation.
Immunohistochemistry was performed using the follow-
ing primary antibodies: glial fibrillary acidic protein
(GFAP, 1:2,000; Dako, Glostrup, Denmark), ionized
calcium-binding adapter molecule 1 (Iba1, 1:2,000;
Wako Chemicals USA Inc., Richmond, VA), synaptophy-
sin (1:1,000; Abcam, Cambridge, MA) and CSPα/
DNAJC5 (AB1576, 1:1,000, Millipore, Temecula, CA).
Densitometry
Densitometry of synaptophysin and CSPα/DNAJC5 im-
munoreactivity was assessed in the cortical ribbon of the
middle frontal gyrus, an area available in all mutation
carriers and non-carriers, and included the gyral crest
and sulcal depth. The intensity of immunoreactivity
(luminance measured as arbitrary values) was determined
following immunohistochemistry of all cases treated in a
single batch using Densita (MicroBrightField, Inc., Williston,
VT) software.
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Ultrastructural methods
Small pieces of tissues from the right palm of formalin-
fixed tissue were processed for transmission electron mi-
croscopy as previously described [5]. Briefly, specimens
were fixed overnight in 3 % glutaraldehyde in Sorensen’s
buffer, osmicated, dehydrated in graded alcohols and
embedded in Epon. Thin sections were cut on an ultra-
microtome, collected on mesh grids, stained with lead
citrate and uranyl acetate and examined with a JEOL
1200 electron microscope.
Immunoblotting
Cells were lysed in radioimmune precipitation assay
(RIPA) buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 % Nonidet P-40 and 0.25 % sodium deoxycholate) plus
1X phenylmethanesulfonylfluoride (PMSF) and 1X
complete protease inhibitor mixture (Sigma, St. Louis,
MO) for 10 min on ice and then spun at 14,000 rpm for
10 min at 4 °C. Protein was subjected to electrophoresis
and transferred to PDVF membrane (BIO-RAD,
Hercules, CA). The primary antibodies were diluted as fol-
lows: CSPα (ADI-VAP-SV003-E; Enzo life science) 1:5000,
HSC70/HSP73 (ADI-SPA-816; Enzo life science) 1:1000,
Synaptobrevin/VAMP2 (104211, Synaptic System) 1:10000,
Syntaxin-1 (110011, Synaptic System) 1:10000, SNAP-25 (
SMI81, Covance) 1:10000, Synaptophysin (ab8049, abcam)
1:5000, Flotillin (C-7, sc-133153, Santa Cruz Biotechnology)
1:5000, β-Actin (A1978, Sigma-Aldrich) 1:5000. The mem-
branes were then incubated with secondary antibodies,
horseradish peroxidase-conjugated anti-mouse or anti-
rabbit IgG (KPL, Gaithersburg, MD) diluted 1:2000 in 4
% nonfat dry milk PBS-T for 1 h at room temperature.
Signals were visualized using Lumigen ECL Ultra
(TMA-6) (Lumigen, Southfield, MI). Densitometric
semi-quantification was performed using ImageJ soft-
ware (National Institutes of Health).
Analysis of Clinical Samples
The Institutional Review Board (IRB) at the Washington
University in Saint Louis School of Medicine approved
the study. Prior to their participation, written informed
consent was reviewed and obtained from family mem-
bers. The Human Research Protection Office (HRPO)
approval number for our ADRC Genetics Core family
studies is 201104178. The neuropathological findings of
AD-ANCL patients were published previously by
Josephson et al. [5], a brief description is found in
Table 1. DNAJC5 mutation identification and screening
was published by Benitez et al. [6]. The clinically early-
stage patient with AD-ANCL belongs to the 7th gener-
ation of this family, identified as (7:3) in the pedigree
(Fig. 1) [6].
Statistical analyses
All data are shown as means ± SEM. For comparison of
two groups, Student’s unpaired two-tailed t test was
used. Data were analyzed using GraphPad Prism, version
5.00 (San Diego, CA).
Case Presentation
Mutation analyses of DNAJC5/CSPα/NCL4B
Sequencing analysis of exon 4 of the DNAJC5 gene
revealed a coding variant heterozygous transversion
change at position c.344 (c.344 T > G) (Fig. 1a) which
Table 1 Demographics of AD-ANCL cases and healthy controls
Individual ID Age at death Gender State Brain wt. (g) PMI (h) Cause of death
1 37 F Case 1160 4.5 Motor vehicle accident
2 49 F Case 1010 13.5 Bronchopneumonia
3 50 F Case 1050 17 Bronchopneumonia
4 50 M Case 1110 22 Inanition
5 53 F Case 1005 8 Parry’s disease
6 70 F Control 1180 16 Carcinoma of colon
7 72 M Control 980 5 Respiratory failure
8 72 F Control 1060 16 Inanition
9 73 F Control 1230 8 Carcinoma of lung
10 81 F Control 1200 21 Myocardial infarction
11 89 F Control 1100 33 Respiratory failure
12 90 F Control 1050 22 Respiratory failure
13 90 M Control 1320 6.5 Bronchopneumonia
14 91 M Control 1170 8.5 Myocardial infarction
15 93 F Control 1155 5 Respiratory failure
Wt weight, PMI post-mortem interval
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results in a leucine-to-arginine amino acid substitu-
tion (Fig. 1b). This mutation was previously found in
other members of the same family with terminal AD-
ANCL [6, 7].
Clinical features of an early stage AD-ANCL patient
A member of a multigenerational family with AD-ANCL
was evaluated as a research volunteer at age 30 and
33 years at the Knight Alzheimer's Disease Research
Center, Washington University, St. Louis, Missouri, as part
of the follow-up of family members. At both visits the
patient was cognitively normal, had no neurological symp-
toms, and had an unremarkable neurological examination.
Patient’s next evaluation was at 36 y, when patient
reported experiencing multicolored visual hallucinations
in the prior 12 months. More recently the patient reported
apparent myoclonus affecting the upper extremities and
had experienced several non-injurious falls. Three weeks
prior to the assessment, patient had an accident while
driving her automobile. The patient had no reported
seizure episodes. The neurologic examination remained
unremarkable and patient again was rated as cognitively
normal. An awake electroencephalogram, however,
showed bilateral epileptiform discharges. The patient was
evaluated seven months later and began medication.
Neuropathology of an early stage AD-ANCL patient
Neuropathological examination of coronal slices re-
vealed no apparent atrophy of the cortical and sub-
cortical gray and white matter (Fig. 2). There were no
changes found in the limbic system or the cerebellum
of this patient. There was some depigmentation of
the substantia nigra (Fig. 2, inset, right panel), com-
pared to normal control (inset, left panel). We per-
formed histological analysis of the brain and found a
marked enlargement of the cortical pyramidal neurons
(Fig. 3a). In affected neurons, there is displacement of
the nucleus to the base of the apical dendrite and a
markedly swollen cell body in comparison to the typ-
ical pyramidal shape of neurons in neocortical layer
III (Fig. 3b). Neurons contained typical AFSM
(Fig. 3c). We also found focal astrogliosis and rela-
tively mild microgliosis adjacent to some swollen neu-
rons in the frontal lobe neocortex (Fig. 3e and g,
respectively).
We also found cuboidal secretory cells containing lipo-
fuscin granules in a palmar sweat gland (Fig. 4a). Elec-
tron microscopy revealed cells containing dense and
granular osmiophilic lipopigment (Fig. 4b) as well as
granular lipopigment and a lipid globule within a cytoso-
mal membrane (Fig. 4c).
Fig. 1 a DNA sequence traces of DNAJC5 Exon 4 of an early stage AD-ANCL patient (top) and wild-type sequence from an age-gender matched
control individual (bottom). b Schematic representation of the DNAJC5 gene encoded protein (top) and main transcript (bottom). Mutation
p.L115R is highlighted in red.
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No changes in levels of CSPα or synaptophysin in the
brains of an early stage AD-ANCL patient
DNAJC5/CSPα (Fig. 5a, b) and synaptophysin (Fig. 5c, d)
immunohistochemistry revealed diffuse neuropil staining
of the cerebral cortex, consistent with synaptic
localization. Densitometry analysis of the DNAJC5/CSPα
and synaptophysin staining was compared with 10 aged
non-mutation carrier (NC) controls (for demographic
data see Table 1). Although there was a trend towards a
decrease in synapse (synaptophysin) density in AD-
ANCL, it was not statistically significant (p = 0.16, two
tailed t-test). Densitometry of DNAJC5/CSPα immuno-
histocemistry was also variable, probably due to fixation
artifacts, and no difference (p = 0.8, two tailed t-test) in
the density of staining between the mutation carriers
and non-carriers was observed (Fig. 5f ).
Changes in levels of synaptic proteins in the brains of
terminal AD-ANCL patients
We previously predicted that the p.L115R mutation
would dramatically decrease the affinity of CSPα for
membranes [6]. Here, we show that mutant CSPα-
p.L115R reduces levels of CSPα in the cytosolic fraction
by 95 % (0.05 ± 0.01 S.E., n = 6, p = 0.001, unpaired t-
test) compared to controls, while the membrane-bound
fraction (detergent soluble) is reduced by ~50 % (0.53 ±
0.03 S.E., n = 6, p = 0.004, unpaired t-test) in the occipital
Fig. 2 Macroscopic findings in the brain of an early stage AD-ANCL patient
with DNAJC5 p.L115R mutation. The cortical ribbon, basal ganglia, and
medial temporal lobe structures at the level of the mammillary bodies
are unremarkable. There is some depigmentation of the substantia
nigra (Fig. 2, inset, right panel) in comparison with a normal subject
(Fig. 2, inset, left panel)
Fig. 3 Microscopy of AD-ANCL patient with DNAJC5 p.L115R mutation. a An enlarged cortical pyramidal neuron with eccentric nucleus in a mutation
(MC) (arrow). b A typical pyramidal neuron in a non-mutation carrier (NC) control (arrow). Stain: Hematoxylin and eosin. c An enlarged neuron contains
stored lipopigment which is autofluorescent under ultraviolet light (arrow). d NC control exhibits modest neuronal accumulation of lipofuscin (arrow).
e, In a MC, there is patchy reactive astrocytosis (GFAP immunohistochemistry) f Sparse reactive astrocytes in a NC control. g There is a modest increase
in the number of activated microglial cells in the frontal neocortex (arrow) in comparison with a NC control (arrow) (h) (g and h, arrows indicate
microglial cells) (Iba1 immunohistochemistry). a-d (scale bar in a) bar = 50 μm; (e-h) (scale bar in e) bar = 50 μm
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lobe of terminal AD-ANCL patients compared to con-
trols (Fig. 6a). Detailed analysis of CSPα-deficient mice
has shown that neurodegeneration in the absence of
CSPα is a consequence of the defective function of
SNAP-25 and SNARE binding proteins [14]. Therefore,
we examined whether the CSPα reduction found in ter-
minal AD-ANCL patients was accompanied by changes
in other synaptic proteins. We found a significant reduc-
tion in several SNARE-complex forming presynaptic
proteins including, but not limited to a 59 % reduction
in SNAP-25 levels, 41 % reduction in synaptobrevin/
VAMP2 levels and a 43 % reduction in syntaxin 1 levels
in brains of terminal AD-ANCL patients compared to
controls. We also found a 36 % reduction in synaptophy-
sin levels and no changes in CSPα’s partner, HSC70
levels (Fig. 6a). The reduction of the presynaptic proteins
was similar across the different brain regions (frontal,
parietal and temporal) or cerebellum among the AD-
ANCL patients (Data not shown). No flash frozen tissue
was obtained from the early stage AD-ANCL patient,
which prevents us from performing the same biochem-
ical analyses.
Discussion
AD-ANCL is a rare multisystem neurodegenerative dis-
order characterized by intracellular accumulation of
macromolecular debris [4, 5], caused by p.L115R (Fig. 1)
and p.L116Δ mutations in DNAJC5/CLN4B/CSPα [6, 7,
8]. Nearly all of our understanding of AD-ANCL is based
on analysis of postmortem tissue from terminal cases [5,
7]. Here, we describe a 37 year old patient in a clinically
early stage of AD-ANCL harboring a p.L115R mutation in
DNAJC5/CSPα. This patient was a member of a multigen-
erational family with AD-ANCL, which has been clinically
and pathologically described by Josephson et al. [5]. The
average age at onset in the other members of this family is
36 ± 2.44 years (range 32–40) with a duration of 9.3 ±
3.3 years (range 5–13). The clinical symptoms start with
new-onset generalized tonic–clonic seizures followed by
dementia (aprox. 3 years), motor impairment and finally
death [5]. Interestingly, most of the histopathological find-
ings found in this patient are indistinguishable from the
changes reported in terminal cases, including the clear
presence of AFSM in the soma of neurons and most
prominent in pyramidal neurons (Fig. 3c) [5]. However,
unlike the terminal cases, there was no brain atrophy or
significant differences in CSPα or synaptophysin in the
neuropil compared to the controls (Fig. 5). The effect of
these mutations on CSPα, a synaptic protein, and how this
results in AD-ANCL has not been established. This study
demonstrates alterations in the neuronal soma, most
likely in the lysosome, of an early-stage of the disease
(Fig. 3a-d). In contrast, massive synaptic degeneration
was only observed in post-mortem tissue from ter-
minal AD-ANCL patients (Fig. 6a, b) [5, 7], suggest-
ing that the dysfunction in the soma of neurons likely
at the lysosomal level occurs before the massive syn-
aptic degeneration as a consequence of the aggregate-
derived toxic effects of the mutation in DNAJC5/
CSPα [16].
Neuronal cell death seems to be correlated with age of
onset and duration of the disease in most NCLs [19]. In
Fig. 4 Fine structure of an early stage AD-ANCL patient with DNAJC5 p.L115R mutation. a Palmar sweat gland with cuboidal secretory cells
containing lipofuscin granules (arrows). b A cell containing dense and granular osmiophilic lipopigment (arrow). c Granular lipopigment (arrow)
and a lipid globule (arrowhead) within a cytosomal membrane. a Toluidine blue; (b and c), Epon-embedded, uranyly acetate stain. Bars: (a),
100 μm; (b), 1 μm; (c), 500 nm
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Fig. 5 (See legend on next page.)
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AD-ANCL there is a remarkable neuronal depletion in
the cortex of the frontal, parietal and temporal lobes of
the AD-ANCL terminal cases [5]. Here, we found min-
imal to no evidence of neuronal loss or cortex atrophy
in a clinically early-stage patient with AD-ANCL in the
examined areas.
Microgliosis and astrogliosis seems to be an early
event, possibly even occurring before neuronal degener-
ation in several NLCs [19, 20] including adult forms [5],
and remains remarkable in very advanced stages of neu-
rodegeneration in the cerebral cortex [5, 19]. Here, we
found microglial and astroglial activation in isolated
areas surrounding the swollen neurons in the cortex of
an early-stage AD-ANCL patient.
Here, we report that terminal AD-ANCL patients ex-
hibit reductions in presynaptic proteins that form the
SNARE complex including SNAP-25, VAMP2 and STX1
(Fig. 6a, b). A similar reduction in SNAP-25 was reported
in CSPα-deficient mice [9, 10, 14] but unlike the findings
in CSPα-deficient mice, terminal AD-ANCL patients ex-
hibit similar HSC70 levels compared to control (Fig. 5b).
Other LSDs also exhibit SNARE defects as a conse-
quence of the primary lysosomal defects [21]. Unfortu-
nately, lysosome function has not been evaluated in
CSPα-deficient mice [12, 16]. In contrast, CSPα-p.L115R
induces dramatic changes in the soma that appear to
precede the synaptic defects. This sequence of events
has been reported in other LSDs where non-lysosomal
mutant proteins affect the intracellular trafficking of
proteins upstream or downstream of the lysosome, in-
cluding synaptic proteins, subsequently producing syn-
aptic dysfunction [22–24].
(See figure on previous page.)
Fig. 5 Immunohistochemistry for CSPα and synaptophysin in the cerebral cortex of an early stage AD-ANCL patient (a) DNAJC5/CSPα immunohistochemistry
in the cerebral cortex of an early stage AD-ANCL patient (zone of staining above arrowhead); the underlying white matter is unstained.
b non-mutation control subject. c Immunohistochemistry for synaptophysin in the cerebral cortex of an early stage AD-ANCL patient
(zone of staining above arrowhead); the underlying white matter is unstained. d non-mutation control subject. Bar: 500 μm. f Quantification of the
intensity of immunoreactivity staining (luminance measured as arbitrary values) (graph). Values represent the mean ± S.E.M. of three independent
experiments using Student’s t test
Fig. 6 Presynaptic protein levels in the brains of terminal AD-ANCL patients. a Representative western blots (top) and semi-quantitative analysis (graph,
bottom) displaying the protein levels of CSPα in the membrane (M-CSPα) (normalized to Flotillin) and cytosolic/soluble (S-CSPα) (normalized to HSC70)
fractions from the occipital lobe of three controls and three terminal AD-ANCL patients. The graphs show the expression level of the indicated proteins
normalized to flotillin or HSC70 expression. b Representative western blots (top) and semi-quantitative analysis (graph, bottom) show the protein levels
of SNAP-25, vesicle-associated membrane protein 2 (VAMP2/ Synaptobrevin), Syntaxin 1 (STX1), and Synaptophysin (SYP) in the occipital lobe from
three controls and three terminal AD-ANCL patients in the membrane fraction. Values represent the mean ± S.E.M. of three independent experiments.
**, p≤ 0.01; ***, p≤ 0.001 using Student’s t test
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We have confirmed and extended the finding that post-
mortem brain samples from terminal AD-ANCL patients
display a large reduction in CSPα levels compared to con-
trols (Fig. 6a) [7, 17, 25]. Interestingly, the levels of
membrane-bound CSPα are decreased 50 % in terminal
AD-ANCL patients (Fig. 6a). CSPα hemizygous mice ex-
hibit a 50 % reduction in the level of CSPα and are pheno-
typically normal [10]. Assuming membrane-bound CSPα
is the main functional fraction, this 50 % reduction alone
would not explain the synaptic changes and neurodegen-
eration found in terminal AD-ANCL patients (Fig. 6a, b).
This suggests that an additional mechanism other than an
isolated reduction in CSPα levels is responsible for the
neurodegeneration found in AD-ANCL. However, we can-
not rule out the possibility that the overall reduction, up
to one third of the control levels, in both soluble and
membrane-bound CSPα found in AD-ANCL patients
could be responsible for the synaptic defects seen.
We also found in brain homogenates from individual
controls that there is a substantial amount of CSPα
present in the soluble/cytosolic fraction (Fig. 6a). CSPα
levels in this particular fraction are dramatically reduced
in AD-ANCL patients (Fig. 6a). The cytosolic CSPα frac-
tion extracts from the rat brain have been described to
interact with HSC70 [26]. The amount of soluble/cytosolic
CSPα depends on both the cell type [27–29] and the activ-
ity of palmitoyl- transferases on CSPα [30]. Thus, it is pos-
sible that human brain expression levels and types of
palmitoyl- transferases vary in different cell types [31] or
that palmitoyl- transferase activity is age-dependent
resulting in a greater soluble/cytosolic CSPα fraction. We
cannot rule out the possibility that this finding is an
artifact or contamination from small vesicles in our
detergent-free fraction. However, the CSPα levels found in
three different individual controls strongly suggest that
this is not an artifact (Fig. 6a). The role of soluble/cyto-
solic CSPα is not clearly defined since the most thor-
oughly studied is membrane-bound CSPα. However, CSPα
exhibits both chaperone and co-chaperone activity that
does not depend on its ability to bind the membrane.
The understanding of how mutations in a “synaptic”
protein can lead to lysosome dysfunction is currently
unclear. Lysosomes are dynamic organelles that receive
and degrade macromolecules from secretory, endocytic,
autophagic and phagocytic membrane-trafficking path-
ways [32]. Lysosomes also serve as a common endpoint
for multiple vesicle-based trafficking systems [32]. CSPα is
critical for maintaining vesicle-membrane fusion events
[28]. The fusion events between lysosomes and endo-
somes, phagosomes, autophagosomes or plasma mem-
brane, are all mediated by the SNARE complexes [32].
The main proteins forming these trans-SNARE complexes
include syntaxin-7, syntaxin-8 (Q-SNARES) and vesicle-
associated membrane protein-8 (VAMP8) and VAMP7
(R-SNARES), in addition to synaptosome-associated pro-
tein of 23 kDa (SNAP23), synaptotagmin-VII and Rab3a
[32], some of which have been identified as CSPα’s part-
ners [16]. Terminal AD-ANCL patients exhibit significant
reductions in SNARE-complex forming proteins (Fig. 6b).
Thus, it is likely that dysfunctional CSPα affects the ma-
chinery that coordinates these lysosomal fusion events
resulting in the formation of the ceroid aggregates and
subsequent swelling of the cellular soma (cortical pyram-
idal neurons and palmar sweat gland) seen in AD-ANCL.
In this report, we describe the clinical and pathological
features of a patient in a clinically early stage of AD-
ANCL with all the pathological cellular changes found in
terminal AD-ANCL cases, but with minimal or no appar-
ent reduction in CSPα or synaptophysin in the neuropil.
In contrast, terminal AD-ANCL patients exhibit signifi-
cant reductions of presynaptic protein levels, including a
significant reduction in CSPα and its main partner SNAP-
25 but not in HSC70 levels. Our analysis of a single brain
region in an early-stage AD-ANCL patient showed a non-
significant trend toward synaptic loss (Fig. 5a). CSPα-defi-
cient mice exhibit a massive neurodegeneration with wide
heterogeneity in the time-course and type of neurons
affected [10]. Thus, it seems possible that this early-stage
AD-ANCL patient might have synaptic losses that are not
obvious in gross immunohistological analyses.
In summary, the widespread neurodegeneration seen
in terminal AD-ANCL patients seems to be a conse-
quence of both the early effects of mutant CSPα in the
soma, most likely on lysosome function, and subsequent
synaptic dysfunction resulting from the reduction in
CSPα levels. We hypothesize that in this AD-ANCL pa-
tient the lysosomal dysfunction (ceroid accumulation)
occurred before neuronal cell death and synaptic
degeneration.
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